Presentation: 2 cc vial, 10 mg/vial, protected with hologram. Comes without solvent.
PT-141, or bremelanotide, belongs to the new class of synthetic proteins that work as melanocortin agonists. It is a peptidic compound under new drug development process known as palatin technology. Its molecular formula is C50H68N14O10; its molecular weight/mass is 1025.2.
This new representative of peptides was synthesized just recently from melanotan-ppeptide, and till now is being participating in few clinical trials with animal models in different countries. To date, the biggest randomized controlled and double-blind clinical studies were done in 2004 and 2007 with looking at safety evaluation, pharmacokinetic features and its pharmacodynamics for males and females respectively. In the end of 2012 the second phase of clinical trial was finished and its results will be published soon.
PT-141’s primary feature is to have positive influence to sexual systemic dysfunction. Unlike other compounds and hormones bremelanotide doesn't affect the vascular system; instead this research compound works by stimulating melanocortin receptors, and that in turn leads to sexual stimulation and to modulation of inflammation.
This peptide is experimental and released for clinical and research use only.